[Federal Register: October 14, 2004 (Volume 69, Number 198)]
[Notices]
[Page 61044-61045]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr14oc04-101]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in Schedule I or II and prior to issuing a
regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on June 29, 2004, Cerilliant Corporation, 811 Paloma Drive, Suite
A, Round Rock, Texas 78664, made application by renewal to the Drug
Enforcement Administration (DEA) for registration as an importer of the
basic classes of controlled substances listed below:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)............................................. I
Methcathinone (1237)......................................... I
N-Ethylamphetamine (1475).................................... I
Gamma hydroxybutyric acid (2010)............................. I
Ibogaine (7260).............................................. I
Tetrahydrocannabinols (7370)................................. I
Mescaline (7381)............................................. I
4-Bromo-2,5-dimethoxyamphetamine (7391)...................... I
4-Bromo-2,5-dimethoxyphenethylamine (7392)................... I
4-Methyl-2,5-dimethoxyamphetamine (7395)..................... I
2,5-Dimethoxyamphetamine (7396).............................. I
3,4-Methylenedioxy- .........
amphetamine (7400).......................................... I
3,4-Methylenedioxymeth- .........
amphetamine (7404).......................................... I
3,4-Methylenedioxymeth- .........
amphetamine (7405).......................................... I
4-Methoxyamphetamine (7411).................................. I
Psilocybin (7437)............................................ I
Psilocyn (7438).............................................. I
Etorphine (9056)............................................. I
Heroin (9200)................................................ I
Pholcodine (9314)............................................ I
Amphetamine (1100)........................................... II
Methamphetamine (1105)....................................... II
Amobarbital (2125)........................................... II
Pentobarbital (2270)......................................... II
Cocaine (9041)............................................... II
[[Page 61045]]
Codeine (9050)............................................... II
Dihydrocodeine (9120)........................................ II
Oxycodone (9143)............................................. II
Hydromorphone (9150)......................................... II
Benzoylecgonine (9180)....................................... II
Ethylmorphine (9190)......................................... II
Meperidine (9230)............................................ II
Methadone (9250)............................................. II
Dextropropoxyphene, bulk (non-dosage forms) (9273)........... II
Morphine (9300).............................................. II
Thebaine (9333).............................................. II
Levo-alphacetylmethadol (9648)............................... II
Oxymorphone (9652)........................................... II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled substances for the manufacture of analytical reference
standards.
Any manufacturer who is presently, or is applying to be, registered
with DEA to manufacture such basic classes of controlled substances may
file comments or objections to the issuance of the proposed
registration and may, at the same time, file a written request for a
hearing on such application pursuant to 21 CFR 1301.43 and in such form
as prescribed by 21 CFR 1316.47.
Any such comments or objections or requests for hearing may be
addressed, in quintuplicate, to the Deputy Assistant Administrator,
Office of Diversion Control, Drug Enforcement Administration, United
States Department of Justice, Washington, DC 20537, Attention: DEA
Federal Register Representative (CCD) and must be filed no later than
November 15, 2004.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e) and (f).
As noted in a previous notice published in the Federal Register on
September 23, 1975, (40 FR 43745-46), all applicants for registration
to import a basic class of any controlled substances in Schedule I or
II are and will continue to be required to demonstrate to the Deputy
Assistant Administrator, Office of Diversion Control, Drug Enforcement
Administration, that the requirements for such registration pursuant to
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c),(d),(e)
and (f) are satisfied.
Dated: September 28, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 04-23054 Filed 10-13-04; 8:45 am]
BILLING CODE 4410-09-P